^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    AVENIO ctDNA Targeted Kit

    Company:
    Roche
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    2ms
    MUTATIONAL ANALYSIS OF CIRCULATING TUMOUR DNA (CTDNA) IN HIGH GRADE SEROUS OVARIAN CANCER (HGSC) USING CANCER PERSONALISED PROFILING BY DEEP SEQUENCING (CAPP-SEQ) (IGCS 2024)
    80% of patients had detectable ctDNA at baseline (mutant DNA copies/ml) with somatic mutations found in TP53, BRCA1, KRAS, NRAS, MET and ERBB2 genes. CNVs were found in EGFR and MET. 69% of all plasmas were ctDNA+.
    Tumor mutational burden • BRCA Biomarker • Circulating tumor DNA
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MET (MET proto-oncogene, receptor tyrosine kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BRCA1 (Breast cancer 1, early onset)
    |
    TP53 mutation • KRAS mutation • BRCA1 mutation • NRAS mutation • MET mutation
    |
    AVENIO ctDNA Targeted Kit
    1year
    OSIRIS: Osimertinib Resistance in Patients With Non-small-cell Lung Carcinoma That Have Progressed. (clinicaltrials.gov)
    P=N/A; Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Aug 2023 --> Aug 2024
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    AVENIO ctDNA Targeted Kit
    |
    Tagrisso (osimertinib)